OS calculated from time of diagnosis; RFS calculated from CR1. Values in square brackets indicate median follow-up time. P values (Gehan-Breslow-Wilcoxon test) indicate survival comparison between responders and nonresponders.

n.r., not reached; RFS, relapse-free survival; SALR, Swedish Acute Leukemia Registry.

*All newly diagnosed patients with AML in CR1 enrolled in the DC vaccination studies NCT00834002 and NCT00965224; 3 patients with AML who were in CR2 or CR3 (UPN02, 16, and 34) and 1 patient with AML who did not reach CR1 (UPN20) were excluded from analysis.

†Observed survival of newly diagnosed patients with AML in CR1 enrolled in SALR; diagnosis from 1997-2014.

‡All study patients who responded to DC vaccination; patient UPN22 had an undefinable response and was excluded from analysis.